Clinical Study

Mnpr-301-001- A Phase 2B/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing The Efficacy And Safety Of Clonidine Mucoadhesive Buccal Tablet To Placebo To Prevent Chemoradiotherapy-Induced Severe Oral Mucositis In Patients With Or

Posted Date: May 20, 2021

  • Investigator: Vinita Takiar
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with chemoradiotherapy.


Must Have Diagnosed Squamous Cell Carcinoma Of The Oropharynx, Radiation Plan Must Include Delivery Of A Cumulative Dose Of 60-72 Gy, Ecog 0-1, Hpv +, No Prior Induction Chemotherapy For Treatment Of Current Malignancy, No Evidence Of A Concomitant Other Malignancy Or Prior Malignancy Within 2 Years. No Clinical Condition Or Infection That Would Make The Patient Unsuitable For The Study Or Unable To Comply With Study Requirements And Follow-Up Visits, No Current Treatment With Sultopride, Clonidine Hydrochloride (Eg, Catapres®), Pentoxifylline Or Pilocarpine


Oropharyngeal Cancer, Opc, Mucositis

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.